LevisonMEKayeD. Treatment of complicated urinary tract infections with an emphasis on drug-resistant Gram-negative uropathogens. Curr Infect Dis Rep2013; 15: 109–115.
2.
RudramurthyKGKumaranRGeethaRK. Etiology and antimicrobial susceptibility pattern of bacterial agents from urinary tract infection in a tertiary care centre. Int J Sci Stud2015; 2: 125–127.
3.
SpellbergBGuidosRGilbertD, et al. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis2008; 46: 155–164.
4.
ChongYShimodaSYakushijiH, et al. Community spread of extended-spectrum beta-lactamase-producing Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis: a long-term study in Japan. J Med Microbiol2013; 62: 1038–1043.
5.
GongJSuDShangJ, et al. Efficacy and safety of high-dose tigecycline for the treatment of infectious diseases: a meta-analysis. Medicine (Baltimore)2019; 98: e17091.
6.
SaderHSJonesRNStilwellMG, et al. Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents. Diagn Microbiol Infect Dis2005; 52: 181–186.
7.
LivermoreDM. Tigecycline: what is it, and where should it be used?J Antimicrob Chemother2005; 56: 611–614.
8.
NixDEMatthiasKR. Should tigecycline be considered for urinary tract infections? A pharmacokinetic re-evaluation. J Antimicrob Chemother2010; 65: 1311–1312.
9.
KruegerWAKempfVAJPeifferM, et al. Treatment with tigecycline of recurrent urosepsis caused by extended spectrum-β-lactamase-producingEscherichia coli. J Clin Microbiol2008; 46: 817–820.
10.
CunhaBA. Pharmacokinetic considerations regarding tigecycline for multidrug-resistant (MDR) Klebsiella pneumoniae or MDR Acinetobacter baumannii urosepsis. J Clin Microbiol2009; 47: 1613.
11.
TuckmanMPetersenPJHoweAYM, et al. Occurrence of tetracycline resistance genes among Escherichia coli isolates from the Phase 3 clinical trials for tigecycline. Antimicrob Agents Chemother2007; 51: 3205–3211.
12.
MuralidharanGMicalizziMSpethJ, et al. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother2005; 49: 220–229.
